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Summary During the 57th annual meeting of the
American Society of Hematology 2015 in Orlando,
Florida, various aspects in the field of hemostaseol-
ogy were presented. The Choosing Wisely® campaign
pointed out the importance of the critical use of di-
agnostic tools to rule out pulmonary embolism and
questioned the relevance of thrombophilia testing
in women undergoing routine infertility evaluation.
Furthermore, the approval of idarucizumab, a specific
antidote for the reversal of the anticoagulant effects
of the direct thrombin inhibitor dabigatran, was high-
lighted. Finally, hemophilia specialists awaited the
results of the SIPPET Trial, which were presented for
the first time during the plenary session. Replace-
ment therapy of previously untreated hemophilia
A patients with plasma-derived factor VIII containing
von Willebrand factor resulted in a lower incidence
of inhibitors compared with patients treated with
recombinant factor VIII.
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● Evidence-based use of diagnostic approaches (e. g.,
CT scans, thrombophilia testing)must be demanded
in hemostaseology.
● Specific antidotes, e.g., idarucizumab for dabiga-
tran, are needed for the reversal of the anticoagulant
effects of direct oral anticoagulants.
● In hemophilia A patients, replacement therapy with
plasma-derived factor VIII containing von Wille-
brand factor led to a lower incidence of inhibitors
compared with treatment with recombinant factor
VIII.
Introduction
The annual meeting of the American Society of Hema-
tology (ASH) 2015 was held in Orlando, Florida. As
expected, the main focus of the meeting was on
novel developments in hematologic diseases; how-
ever, different topics in the field of hemostaseology
– from thrombophilia testing to treatment options
in hemophilia – were also discussed. It should be
pointed out that very important issues in hemostase-
ology, including perioperative bridging of anticoagu-
lation in patients with atrial fibrillation [1] or reversal
of direct oral anticoagulants [2, 3], were already pre-
sented during the meeting of the International Society
of Thrombosis and Haemostasis in Toronto in June
and therefore published earlier this year. The high-
light of the congress for hemophilia specialists was
undoubtedly the first presentation of the results of the
SIPPET trial, which will probably have a huge impact
on the choice of factor VIII product (plasma-derived
vs. recombinant) for the treatment of patients with
hemophilia A [4].
This short review summarizes the clinically most
relevant topics in hemostaseology from the ASHmeet-
ing 2015 in the context of previously published data.
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Table 1 Clinical assessment of the probability of PE using
Wells’ Criteria [6, 7]
Symptoms and patient history Points
Clinical symptoms of DVT (leg swelling, pain with palpation) 3.0
Other diagnosis less likely than PE 3.0
Heart rate >100/min 1.5








DVT deep vein thrombosis, PE pulmonary embolism
The ASH Choosing Wisely® campaign 2015
Initiated in 2013, the ASH Choosing Wisely® Task
Force annually announces hematologic tests and
treatments of questionable clinical value, which in-
crease costs with a low likelihood of benefit and even
expose patients to potential harm. Noteworthy, in
the last 2 years several of the tests and treatments
highlighted were in the field of coagulation, reflecting
the need for evidence-based treatment guidelines [5,
6]. This year the ASH committee released a list of
tests and procedures based on Non-ASH Choosing
Wisely® recommendations from other medical so-
cieties with relevance to hematology. Nevertheless,
also in 2015, two out of five recommendations were
related to hemostaseology. One of them was initially
from 2012 from the American College of Radiology
and recommended against the imaging for suspected
pulmonary embolism (PE) without moderate or high
pretest probability of PE. The probability of PE can
be assessed by using clinical symptoms and the pa-
tient history in the Wells score [7, 8] (see Table 1).
In the case of a low probability, PE might be ruled
out by normal D-dimer levels without further imag-
ing and thereby unnecessary exposure to radiation
can be avoided. The specificity of this approach has
been prospectively shown in several publications [9].
Another recommendation was based on the Ameri-
can Society for Reproductive Medicine. The authors
questioned the clinical relevance of routinely order-
ing thrombophilia testing for patients undergoing
a routine infertility evaluation. In several studies an
association between different types of thrombophilia
and miscarriage, pregnancy loss, as wells as preg-
nancy complications was shown; however, the num-
bers are within a very wide range and inconsistent
(summarized in [10]). Moreover, large prospective
studies showing that the use of either low-molecular-
weight heparin or platelet inhibition as well as the
combination of both can lead to a higher chance of
a successful pregnancy in women with thrombophilia
are lacking [11]. In conclusion, thrombophilia testing
does not affect the treatment of infertile woman.
Idarucizumab: antidote for the reversal of
anticoagulant effects of dabigatran
In general, all clinical studies of patients suffering
from atrial fibrillation or deep vein thrombosis/
pulmonary embolismhave shown positive risk–benefit
analysis of direct oral anticoagulants (DOAC) com-
pared with vitamin K antagonists (VKA), particularly
when it comes to bleeding complications with the
exception of gastrointestinal bleeds. Especially the
risk of intracerebral bleeding was lower in patients
treated with DOACs than with VKA [12–17]. Lately,
these findings have been confirmed by real-life data
[18, 19]. However, bleeding complications and other
emergency situations like accidents or the need for ur-
gent surgery can obviously still occur, requiring rapid
reversal of these drugs. Until 2015 the treatment
options in emergency situations were limited. Guide-
lines recommended the use of supportive measures
(e. g., mechanical compression, surgical procedures,
fluid replacement) in the case of moderate to severe
bleedings; in life-threatening bleedings, prothrombin
complex concentrates (PCC) or activated PCC (factor
VIII inhibitor bypass activity, FEIBA) should be ad-
ministered [20]. Alternatively to PCC, the thrombin
inhibitor dabigatran can be removed by hemodialysis
([21] Fig. 1). The recommendation for the use of PCC
is primarily based on in vitro assays, ex vivo tests,
or animal studies. However, these studies revealed
variable responses of the DOACs toward the PCC [22,
23], but in the case of an emergency an exact predic-
tion of the potential effects is necessary. Therefore for
the reversal of DOACs, specific antidotes with a rapid
onset of action, high binding affinity to the target pro-
tein, and no effects on the coagulation cascade itself
are needed. During the ASH meeting in 2015, Ken-
neth Bauer highlighted Idarucizumab (Praxbind®),
the first specific antidote for the thrombin inhibitor
dabigatran in the session on clinical applications of
newly approved drugs. Idarucizumab is a humanized
monoclonal antibody fragment that has been specif-
ically developed for the reversal of dabigatran [24].
Earlier studies have demonstrated that idarucizumab
restores dabigatran-prolonged coagulation parame-
ters to baseline values, not only in healthy volunteers,
but also in the elderly and patients with chronic kid-
ney disease [25]. Idarucizumab binds specifically to
unbound and thrombin-bound dabigatran with an
affinity approximately 350-fold higher than the affin-
ity of dabigatran for thrombin. Once dabigatran is
complexed to idarucizumab, the anticoagulant effects
are neutralized. In a recently published phase III
trial, idarucizumab was used in a fixed dose of 2 ×
2.5 g in patients with either life-threatening bleeding
or requiring emergency surgery or invasive proce-
dures. Idarucizumab not only completely reversed
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Fig. 1 Recommendations for the treatmentofbleedingcomplicationsor urgent interventionsoccurringduring treatmentwithdirect
oral anticoagulants (adapted from Heidbuchel et al. [20])
the anticoagulant effects of dabigatran within min-
utes as demonstrated by various laboratory tests, but
it also led to a normal intraoperative hemostasis in
the majority of patients based on the assessment of
the surgeons involved during the procedures [2]. Fi-
nally, in late 2015, idarucizumab was approved by the
Food and Drug Administration (FDA) and European
Medicines Agency (EMA) for the treatment of dabiga-
tran-induced bleedings.
A different approach is used for the specific reversal
of the factor Xa inhibitors. Andexanet alfa (Annexa®)
is a recombinant modified human factor Xa decoy
protein that is catalytically inactive but retains the
ability to bind factor Xa inhibitors in the active site,
thereby restoring the activity of endogenous factor
Xa [26]. In phase II/III studies, intravenous adminis-
tration of andexanet alfa resulted in dose-dependent
rapid reversal of the anticoagulant effects of the factor
Xa inhibitors in healthy volunteers. Reversal was as-
sessed as the reduction in anti-factor Xa activity and
unbound factor Xa inhibitor concentrations, as well
as the restoration of thrombin generation. Because of
the short half-life of andexanet alfa, this agent was also
administered as a bolus injection followed by contin-
uous infusion [3, 25]. A study focusing on the effects
of andexanet alfa on bleeding complications during
treatment with factor Xa inhibitors is still ongoing.
Owing to the urgent need for a specific antidote for
factor Xa inhibitors, the approval of the drug is ex-
pected as soon as the results of the ongoing study are
available.
Treatment–related development of anti-factor VIII
antibodies
Finally, Flora Peyvandi presented the data of the SIP-
PET study (Survey of Inhibitors in Plasma-Product
Exposed Toddlers) during the plenary session of the
2015 ASH meeting [4]. The aim of this prospective,
multicenter, open-label, randomized study was to
compare the incidence of factor VIII (FVIII) inhibitors
with plasma-derived FVIII concentrates containing
von Willebrand factor versus recombinant FVIII con-
centrates in previously untreated patients (PUPs) with
severe hemophilia. Inhibitor development is the most
challenging complication of hemophilia treatment. It
not only causes a high economic burden for a chronic
disease, but also leaves FVIII treatment ineffective
thereby increasing the risk of bleeding complications.
A number of risk factors have been identified for
the development of FVIII inhibitors in children with
hemophilia A, including: disease severity, defects
in the FVIII gene, ethnicity, and number of expo-
sure days to FVIII [27, 28]. There is also an ongoing
discussion whether recombinant FVIII products are
more immunogenic than plasma-derived products.
In 2013, the RODIN (Research of Determinants of
INhibitor development) study, to date the largest
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multicenter observational cohort study included 574
PUPs with severe hemophilia A, published its find-
ings. In this study, 177 patients (32%) developed in-
hibitors; however, recombinant and plasma-derived
FVIII products conferred similar risks of inhibitor
development. The content of von Willebrand factor
in the products and switching among products were
not associated with the risk of inhibitor development.
Interestingly, second-generation full-length recom-
binant products were associated with an increased
risk, as compared with third-generation products
[29]. However, the study was criticized because of
the partially retrospective design as well as the unbal-
anced cohort groups. In the SIPPET trial, 303 patients
were screened, and finally 251 were analyzed. In
general, the higher number of PUPs developing in-
hibitors compared with those in the RODIN trial was
striking. Inhibitors developed in 26.8% of patients
treated with plasma-derived factor VIII and 44.5%
with recombinant factor VIII; recombinant factor VIII
was associated with an 87% higher incidence than
plasma-derived factor VIII. When the analysis was
restricted to recombinant factor VIII products other
than second-generation full-length recombinant fac-
tor VIII, the effect estimates remained similar for all
inhibitors. In contrast to the data of the RODIN trial,
Peyvandi and her team concluded that PUPs treated
with plasma-derived FVIII containing von Willebrand
factor had a lower incidence of inhibitors than those
treated with recombinant FVIII.
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